Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 53-61, January 2003

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy☆☆

Department of Radiation Oncology, University of Florida, Gainesville, FL.

Abstract 

It has been well established that the vascularization of solid tumors is a prerequisite if a clinically relevant size is to be reached. For progressive tumor growth, the vessel network must continuously expand to satisfy the neoplastic cells' nutritional needs and waste product removal requirements. This utter reliance of the tumor on its vasculature provides a logical target for new approaches to cancer therapy. Indeed, there currently exists a great deal of enthusiasm for the development of interventions that compromise the growth and/or function of the tumor neovasculature. Two primary directions are being pursued. Inhibitors of angiogenesis seek to interrupt the angiogenic process to prevent new vessel formation. Antivascular approaches aim to cause direct damage to the tumor endothelium and thus lead to extensive secondary neoplastic cell death. The application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies. Copyright 2003, Elsevier Science (USA). All rights reserved.

 

 Supported by the U.S. National Cancer Institute (PHS grants CA84408 and CA89655).

☆☆ Dietmar W. Siemann serves as a consultant for AstraZeneca Pharmaceuticals and Oxigene Inc.

 Address reprint requests to Dietmar W. Siemann, PhD, Department of Radiation Oncology, University of Florida Shands Cancer Center, Box 100385, Gainesville, FL 32610.

PII: S1053-4296(03)50008-X

doi:10.1053/srao.2003.50005

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 53-61, January 2003